Co-founder & CEO @daphnezohar presented at #JPM26 sharing our recent progress & path forward as we tackle some of the biggest medical problems our population is facing today. Co-founders Steve Paul (Chair) & Michael Chen (CSO) joined for Q&A. #depression #anxiety #neuropsychiatry

Our Co-founder & CEO, @daphnezohar, will present at #JPM26 on Jan. 12 at 9:30AM PT. She’ll be joined by Steve Paul, M.D., Co-founder & Chair & Michael Chen, Ph.D., Co-founder & CSO, during the Q&A portion of the presentation. https://t.co/W6aMQYFovI

This year, we've made meaningful progress at Seaport from clinical milestones w/ the Ph2b BUOY‑1 study of GlyphAllo™ in #MDD (w/ or w/o anxious distress) & a Ph1 study of GlyphAgo™ for treatment of #GAD to moments together, made possible by our incredible team. #HappyHolidays!

Candid convo between 2 biotech leaders: CEO @daphnezohar & Kate Haviland (former Blueprint Medicines CEO) on building & leading high performing teams, having a “truth-seeking” mentality, small biotechs successfully commercializing medicines & path to Blueprint's $9B+ acquisition.

Today at 10AM ET our CFO, Lauren White, & CSO, Michael Chen, PhD, will present at the @RBC Capital Markets Healthcare Private Company Conference. Members of our team will also participate in 1x1 meetings. Tune in: https://t.co/tdhidjbBeB Replays: https://t.co/schqbRu0vj

#AES25: Data further validate Glyph’s ability to enhance oral bioavailability & expand therapeutic reach w/ successful application of Glyph to another class of clinically validated molecules previously held back by limitations Glyph’s designed to solve. https://t.co/lF879j5li9

Members of our management team will present at the 2025 @RBC Capital Markets Healthcare Private Company Conference on Dec. 11 at 10AM ET & will participate in 1x1 meetings at the conference. Press release: https://t.co/SeJQ41P1EU Live & archived webcast: https://t.co/o9ZiNd1g4j

Team members joined @afspnational's “Out of the Darkness” walk in Boston to raise awareness for suicide prevention. Our CMO, Tony Loebel, serves on AFSP's board, aligning w/ our mission to serve those w/ #mentalhealth conditions like #depression & #anxiety. Hear more from Tony!

Our CEO @daphnezohar joined the Making Medicine podcast to talk biotech, policy, & Seaport’s mission. Her take on price controls? The real impact would fall on patients, who are at the center of our work at Seaport. Hear her response in the full episode:

#HappyThanksgiving! Ahead of the holiday, we assembled care packages for @RosiesPlace - a women's shelter in Boston - & enjoyed time together at a holiday lunch. Giving back reminds us that we're here to serve those living w/ #mentalhealth conditions like #depression & #anxiety.

Today Co-Founder & Board Chair Dr. Steve Paul joins @SocialTinsWorld’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® & Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar)

Thanks to the NEVYs for nominating us for the Powerhouse Healthcare Company of the Year at the #NEVYs25Awards! Great progress this year w/ the launch of two clinical trials & we look forward to making a difference for those w/ #neuropsychiatric conditions: https://t.co/5CbJTWoDQW

Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the @Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference. Tune in: https://t.co/4BLDOQohnV Replay available here: https://t.co/D7tmniKmgm

Members of our management team will present at the @Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference. Press release: https://t.co/QkSER2JG7s Live & archived webcast here: https://t.co/o9ZiNd0IeL

Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety

Co-Founder & CEO, @daphnezohar joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: https://t.co/cDd1wUPtS4) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: https://t.co/8KAungjVdn). Join us at #USAIC26: https://t.co/esi8O5aSko

“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @DaphneZohar, shows us how it's done. Named a @GoldmanSachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.

At the #StatusList dinner last night I was asked what I would change about our industry. My response: the likelihood of making it from discovery to FDA approval is ~1% & takes 10-15 yrs yet the incentives focus only on rewarding the successes w/ so much waste & lost knowledge. We

Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.

Members of our exec team joined @FierceBiotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. https://t.co/bT43jDM5bL